Licochalcone a Induces ROS-Mediated Apoptosis through TrxR1 Inactivation in Colorectal Cancer Cells

Biomed Res Int. 2020 May 27:2020:5875074. doi: 10.1155/2020/5875074. eCollection 2020.

Abstract

Licochalcone A (LCA) exhibited anticancer activity through modulating reactive oxygen species (ROS) levels in some cancer cells and has been evidenced to suppress colorectal cancer (CRC) formation and progression. However, whether LCA mediates the progression of CRC by regulating ROS production remains unclear. To address this, HCT-116 cells were treated with LCA, resulting in G0/G1 phase arrest, apoptosis, and high ROS generation, which were attenuated by N-acetyl-L-cysteine, a ROS inhibitor. In addition, LCA suppressed the expression of thioredoxin reductase 1 (TrxR1) in HCT-116 cells, leading to high ROS levels and apoptosis. Moreover, LCA administration combined with TrxR1 inhibition further enhanced the production of ROS and apoptosis in HCT-116 cells compared to LCA administration or TrxR1 inhibition alone. These results demonstrated that LCA might enhance the production of ROS by targeting TrxR1, leading to apoptosis in HCT-116 cells, which provides potential insight for the interventional treatment of CRC.

MeSH terms

  • Antineoplastic Agents / administration & dosage*
  • Apoptosis / drug effects*
  • Cell Cycle Checkpoints / drug effects
  • Chalcones / administration & dosage*
  • Colorectal Neoplasms / metabolism*
  • HCT116 Cells
  • Humans
  • Reactive Oxygen Species / metabolism*
  • Signal Transduction / drug effects
  • Thioredoxin Reductase 1 / metabolism*

Substances

  • Antineoplastic Agents
  • Chalcones
  • Reactive Oxygen Species
  • TXNRD1 protein, human
  • Thioredoxin Reductase 1
  • licochalcone A